共 271 条
[1]
Stinchcombe TE(2008)Considerations for second-line therapy of non-small cell lung cancer Oncologist 13 28-36
[2]
Socinski MA(2008)Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (interest): a randomised phase III trial Lancet 372 1809-18
[3]
Kim ES(2006)Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 24 3831-3837
[4]
Hirsh V(2010)Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 521-529
[5]
Mok T(2009)Gefitinib or carboplatin -paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957
[6]
Socinski MA(2002)Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92-98
[7]
Gervais R(2001)Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non small cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 3210-3218
[8]
Wu YL(2000)Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095-2103
[9]
Li LY(2000)Second-line chemotherapy for non-small-cell lung cancer Curr Oncol Rep 2 96-101
[10]
Watkins CL(2004)Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589-1597